CryoLife Company

Artivion is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company, using its proprietary SynerGraft® technology processes the CryoValve® SG pulmonary heart valve and CryoPatch® SG pulmonary cardiac patch, both of which have FDA 510(k) clearance for specific indications. The Company's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue® is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections. The Company's BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. Artivion distributes PerClot®, an absorbable powder hemostat, in the European Community. Artivion, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of cardiovascular disease and the sale of devices that treat severe Angina. Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR). In addition, Artivion's subsidiary Hemosphere, Inc. markets the HeRO Graft, which is a solution for end-stage renal disease in certain hemodialysis patients. Artivion's headquarters are located in Kennesaw, Georgia, a suburb of northwest Atlanta.